Last updated: June 15, 2026
Wyeth LLC v. Apotex Inc. (1:17-cv-00168): Litigation summary, claims, and outcome analysis
What is Wyeth LLC v. Apotex Inc. 1:17-cv-00168 about?
The docket entry labeled Wyeth LLC v. Apotex Inc. | 1:17-cv-00168 is a U.S. patent infringement case in which Wyeth LLC sued Apotex Inc. over the launch and/or filing activity for a Wyeth-branded pharmaceutical product with asserted infringement of one or more patents tied to the active ingredient and/or related formulations and/or methods of use.
Core litigation framework (typical for this case pattern):
- Asserted patents are listed in FDA’s Orange Book for the reference product.
- Apotex’s conduct is tied to an FDA pathway filing that triggers Hatch-Waxman remedies, commonly via a Paragraph IV certification.
- The case determines whether Apotex can launch a generic earlier than the patent-driven exclusivity window, subject to any settlement terms.
Which patents were asserted in Wyeth v. Apotex 1:17-cv-00168?
No patent numbers, asserted claims, or specific publication/application identifiers are provided in the available prompt content. Without those, an accurate “which patents” and “what claims” mapping cannot be produced.
What procedural posture did the case reach (motions, Markman, trial, appeal)?
No procedural milestone dates (complaint filing, answer, claim construction, summary judgment, trial, verdict, appeal) are included in the prompt content. Without case-log dates and order titles, a litigation timeline cannot be stated correctly.
How does this case relate to Orange Book listing and FDA Paragraph IV certifications?
This matter follows the standard Hatch-Waxman pattern, where the manufacturer of a reference product (here, Wyeth LLC) typically asserts that the generic (here, Apotex Inc.) infringes one or more listed patents for the reference drug.
However, the prompt does not include the drug name, NDA/BLA number, Orange Book listing identifiers, or the Paragraph IV patent list Apotex certified against. Those elements are required to tie the litigation to specific regulatory certifications and expiration timelines.
What is the infringement theory (formulation, method-of-use, or manufacturing)?
Wyeth suits in this posture often assert at least one of the following patent categories:
- Formulation/composition of matter (drug substance or dosage form)
- Method-of-use (indication-specific or dosing regimen)
- Manufacturing/process (controls, intermediates, or production method)
The prompt does not provide the asserted patent families or the infringement contentions, so the infringement theory cannot be specified without risking factual error.
What settlement outcome, dismissal, or judgment occurred?
No disposition information is included in the prompt content (settlement date, consent judgment, dismissal without prejudice, final judgment, or appellate disposition). Without an order-of-record or outcome status, a “what happened” summary cannot be completed accurately.
What does the result mean for generic launch risk and exclusivity timing?
A litigation outcome typically impacts:
- Launch date constraints tied to patent expiration
- Design-around feasibility (whether Apotex can launch via noninfringing formulation or carve-outs)
- Risk of further litigation against follow-on ANDAs or amended certifications
But because the prompt does not include the specific reference drug, the Orange Book patents, the certified patents, or the disposition, any launch-risk conclusion would be unsupported.
How strong is Wyeth’s patent estate against Apotex for this product?
Patent strength analysis requires:
- asserted patent numbers and remaining term at suit filing
- claim construction outcomes (if any)
- validity challenges outcomes (if litigated)
- whether patents overlap across formulation/method-of-use families
- whether any patents were held invalid or not infringed
No asserted-patent identifiers or any substantive rulings are provided, so the strength cannot be quantified.
How does Apotex’s litigation stance typically shape outcomes in Hatch-Waxman cases?
Without the case’s filings (invalidity contentions, noninfringement arguments, estoppel/anticipation/obviousness positions) the defendant’s litigation posture cannot be characterized.
What comparable cases (same patent family, same product) are relevant?
Comparative analysis requires knowing:
- the drug and therapeutic area
- the patent family identifiers
- any related settlements or parallel litigation
None of those are present in the prompt content.
Key takeaways
- This docket caption indicates a U.S. patent infringement dispute in a Hatch-Waxman style posture, but the prompt contains no drug identity, asserted patents, procedural milestones, or disposition.
- A litigation summary that names specific patents, claims, dates, and outcome cannot be completed from the provided input without introducing inaccuracies.
FAQs
- What court heard Wyeth LLC v. Apotex Inc. 1:17-cv-00168, and what is the venue?
- Which Orange Book patents did Apotex challenge in its Paragraph IV certification for this case?
- Were any patents found not infringed, invalid, or settled in Wyeth v. Apotex 1:17-cv-00168?
- Did the case involve claim construction (Markman) for formulation, method-of-use, or manufacturing claims?
- What is the effect of the case disposition on generic launch timing for the associated ANDA?
References (APA)
- No source material with docket orders, asserted patents, or FDA/Orange Book identifiers is included in the prompt content.
